Zealand Pharma 미래 성장

Future 기준 확인 5/6

Zealand Pharma (는) 각각 연간 65.8% 및 50.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 48.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -7.3% 로 예상됩니다.

주요 정보

65.8%

수익 성장률

48.1%

EPS 성장률

Biotechs 수익 성장	43.1%
매출 성장률	50.4%
향후 자기자본 수익률	-7.3%
애널리스트 커버리지	Good
마지막 업데이트	15 Nov 2024

최근 미래 성장 업데이트

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Recent updates

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Mar 17

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Oct 03

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Aug 14

수익 및 매출 성장 예측

CPSE:ZEAL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (DKK Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	2,642	1,076	-22	-164	10
12/31/2025	1,785	353	2,219	1,758	11
12/31/2024	452	-700	-1,077	-1,023	10
9/30/2024	77	-1,053	-711	-691	N/A
6/30/2024	368	-712	-538	-508	N/A
3/31/2024	344	-739	-479	-453	N/A
12/31/2023	343	-704	-449	-426	N/A
9/30/2023	343	-760	-778	-758	N/A
6/30/2023	92	-986	-782	-771	N/A
3/31/2023	107	-1,064	-831	-822	N/A
12/31/2022	104	-966	-954	-942	N/A
9/30/2022	93	-855	-999	-978	N/A
6/30/2022	104	-845	-1,083	-1,060	N/A
3/31/2022	114	-608	-1,182	-1,161	N/A
12/31/2021	109	-755	-1,234	-1,212	N/A
9/30/2021	158	-925	-1,183	-1,181	N/A
6/30/2021	161	-1,012	-1,085	-1,071	N/A
3/31/2021	347	-909	-870	-844	N/A
12/31/2020	192	-669	-714	-689	N/A
9/30/2020	301	-660	-618	-580	N/A
6/30/2020	255	-545	-670	-632	N/A
3/31/2020	54	-624	-698	-671	N/A
12/31/2019	41	-572	-433	-409	N/A
9/30/2019	43	-508	-408	-391	N/A
6/30/2019	33	524	927	-346	N/A
3/31/2019	28	551	952	-320	N/A
12/31/2018	38	581	810	-461	N/A
9/30/2018	35	601	853	-417	N/A
6/30/2018	74	-361	N/A	-310	N/A
3/31/2018	68	-346	N/A	-320	N/A
12/31/2017	136	-274	N/A	-279	N/A
9/30/2017	306	-112	N/A	-64	N/A
6/30/2017	307	-100	N/A	-113	N/A
3/31/2017	306	-102	N/A	-52	N/A
12/31/2016	231	-157	N/A	41	N/A
9/30/2016	221	-138	N/A	-114	N/A
6/30/2016	189	-158	N/A	-128	N/A
3/31/2016	188	-139	N/A	-120	N/A
12/31/2015	188	-114	N/A	-225	N/A
9/30/2015	27	-246	N/A	-216	N/A
6/30/2015	78	-178	N/A	-149	N/A
3/31/2015	75	-147	N/A	-146	N/A
12/31/2014	154	-65	N/A	-42	N/A
9/30/2014	151	-47	N/A	-50	N/A
6/30/2014	95	-98	N/A	-100	N/A
3/31/2014	92	-97	N/A	-85	N/A
12/31/2013	7	-184	N/A	-170	N/A

애널리스트 미래 성장 예측

수입 대 저축률: ZEAL 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 1.2% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: ZEAL (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: ZEAL 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: ZEAL 의 수익(연간 50.4% ) Danish 시장( 9.6% 보다 빠르게 성장할 것으로 예상됩니다. 9.6% 연간).

고성장 수익: ZEAL 의 수익(연간 50.4% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: ZEAL (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

Zealand Pharma 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Forecast to breakeven in 2025

Consensus EPS estimates fall by 14%

Consensus revenue estimates fall by 11%

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Consensus EPS estimates fall by 40%

Recent updates

Employee Representative Director recently sold kr.1.3m worth of stock

Forecast to breakeven in 2025

Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Consensus EPS estimates fall by 14%

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Insufficient new directors

Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt

President & CEO recently sold kr.31m worth of stock

Consensus revenue estimates fall by 11%

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 40%

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Consensus forecasts updated

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to kr.229

Zealand Pharma Announces CEO Changes

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Full year 2021 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Consensus forecasts updated

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Price target decreased to kr.228

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Price target decreased to kr.236

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Consensus EPS estimates fall to -kr.28.75

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection